China Pharmaceutical Glass Packaging Industry Report, 2014-2017
  • June 2015
  • Hard Copy
  • USD $1,650
  • Pages:60
  • Single User License
    (PDF Unprintable)       
  • USD $1,550
  • Code: ZYM065
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,850
      

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Chinese pharmaceutical packaging market reached RMB72 billion, up 10.6% from a year earlier.

As a traditional form of pharmaceutical packaging bottle, pharmaceutical glass bottle took up a large proportion of the Chinese pharmaceutical packaging market in initial development stage of the packaging market. However, affected by negative factors like the substitution of new packaging materials (plastics and aluminum foil) and continuous decline in purchase prices of packaging materials quoted by pharmaceutical companies due to reform in medical system, China pharmaceutical glass packaging industry has developed sluggishly, with its market share standing at estimated 45% or so for the time being.

Due to low barrier to entry, China’s pharmaceutical glass industry has been large but not strong as a whole, with low and medium-end products struggling with huge overcapacity and high-end products relying on imports. At present, developed countries around the world all use level I waterproof neutral borosilicate glass, while China still mostly adopts low borosilicate glass, soda-lime glass and almost domestically unique “semi-neutral borosilicate pharmaceutical glass” (its chemical stability cannot meet neutral requirements; the heavy metal content in glass is not defined clearly; dimensions are not accurate).

The production of neutral borosilicate glass faces dual barriers of raw materials and tube-making technology, which have been still controlled by foreign companies so far, resulting in persistently high production costs and limited applications. In 2012, German Schott AG, a world well-known pharmaceutical glass company, together with Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., announced to establish a joint venture that would engage in pharmaceutical packaging, an important sign marking localization of pharmaceutical glass. But, even for the joint venture, it has to buy glass tube produced by Schott abroad.

However, the defect of low borosilicate glass easily flaking causes safety risks to health of users, so it is imperative to promote neutral borosilicate glass. Market demand for neutral borosilicate glass pharmaceutical containers has been growing by more than 20% over the past two years. More and more pharmaceutical players started to use neutral borosilicate glass, especially for high value-added products. For example, Buchang Pharma employs neutral borosilicate glass packaging materials for all its Danhong Injections, and some innovative R&D-oriented pharmaceutical companies like Jiangsu Hengrui Medicine Co., Ltd. also adopt neutral borosilicate glass.

With years of development and competition, the Chinese pharmaceutical glass business market still finds a relatively low level of concentration, but competitively leading companies have emerged in some market segments, especially in prefilled syringe market.

There are only five companies that have obtained assemblages for prefilled syringes in China, i.e., foreign-funded BD and Gerresheimer and domestic Shandong Weigao Group Medical Polymer, Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd. and Shandong Pharmaceutical Glass Co., Ltd.

By virtue of first-mover advantage and developed marketing network, Shandong Weigao Group Medical Polymer sold about 85.85 million prefilled syringes in 2014, accounting for more than 50% of the market in China, followed by foreign brands such as BD and Gerresheimer with market share of about 25%, and Zibo Minkang Pharmaceutical and Shandong Pharmaceutical Glass (the remaining). In addition, Shandong Weigao Group Medical Polymer still plans to implement the 50-million prefilled syringes project, which is expected to further raise the company’s share in prefilled system market.

China Pharmaceutical Glass Packaging Industry Report, 2014-2017 highlights the followings:
20120114.gifStatus quo, market size, import & export, downstream demand and development forecast of China pharmaceutical glass industry;
20120114.gifStatus quo, competitive landscape and price of China prefilled syringe industry;
20120114.gifOperation, pharmaceutical glass business and development prospects of 4 global and 6 domestic pharmaceutical glass packaging companies.

1 Overview of Pharmaceutical Glass Packaging Materials
1.1 Definition and Classification
1.2 Industry Chain

2 Development of China Pharmaceutical Glass Industry
2.1 Status Quo
2.2 Market Size
2.3 Competitive Landscape
2.4 Import & Export
2.5 Prefilled Injection System
2.5.1 Definition and Classification
2.5.2 Status Quo
2.5.3 Competitive Landscape
2.5.4 Price
2.6 Downstream Demand
2.6.1 Vaccine
2.6.2 Blood Product
2.6.3 Insulin
2.6.4 Heparin
2.6.5 Interferon
2.6.6 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
2.7 Development Trend

3 Major Pharmaceutical Glass Companies
3.1 Becton, Dickinson and Company
3.1.1 Profile
3.1.2 Operation
3.1.3 Revenue Structure
3.1.4 Pharmaceutical Packaging Materials Business
3.1.5 Business in China
3.2 Gerresheimer AG
3.2.1 Profile
3.2.2 Operation
3.2.3 Revenue Structure
3.2.4 Business in China
3.3 SCHOTT AG
3.3.1 Profile
3.3.2 Operation
3.3.3 Pharmaceutical Packaging Materials Business
3.3.4 Business in China
3.4 Nipro Medical Corporation
3.4.1 Profile
3.4.2 Operation
3.4.3 Revenue Structure
3.4.4 Pharmaceutical Packaging Materials Business
3.4.5 Business in China
3.4.5.1 ChengDuPingYuanNipro Pharmaceutical Packaging Co., Ltd.
3.4.5.2 Jilin NiproJiaheng Pharmaceutical Packaging Co., Ltd.
3.4.5.3 Anyang NiproChangda Pharmaceutical Packaging Co., Ltd.
3.5 Shandong Pharmaceutical Glass Co., Ltd
3.5.1 Profile
3.5.2 Operation
3.5.3 Revenue Structure
3.5.4 Gross Margin
3.5.5 Development Prospects and Forecast
3.6 Shandong Weigao Group Medical Polymer Co., Ltd. 
3.6.1 Profile
3.6.2 Operation
3.6.3 Revenue Structure
3.6.4 Gross Margin
3.6.5 R&D and Investment
3.6.6 Major Customers
3.6.7 Pharmaceutical Packaging Materials Business
3.6.8 Development Prospects and Forecast
3.7 Cangzhou Four Stars Glass Co., Ltd.
3.8 Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
3.9 Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
3.10 Linuo Glassworks Group

4 Summary and Forecast
Classification and Applications of Pharmaceutical Glass
New Pharmaceutical Glass Packaging and Application
Diagram of Pharmaceutical Glass Packaging Industry Chain
Market Size of China Pharmaceutical Packaging Industry, 2010-2014
Output of Human Powder Injection (Including Freeze-dried) and Injection in China, 2010-2014
Output of Large Volume Parenterals (LVPs) in China, 2010-2014
Revenue and YoY Growth of Veterinary Drug Industry in China, 2007-2014
Import and Export Volume of Glass Ampoule in China, 2011-2014
Import and Export Value of Glass Ampoule in China, 2011-2014
Average Import and Export Price of Glass Ampoule in China, 2011-2014
Materials for Prefilled Syringes
Classification of Prefilled Syringe and Structural Diagram
Prefilled Syringe Suppliers in China and Their Products
Major Prefilled Syringe Manufacturers and Their Capacity, 2014
Price of Some Prefilled Drugs in China, 2010-2014
Market Size of Pharmaceuticals Industry in China, 2011-2015
Lot Release Volume of EPI an Extra EPI in China, 2007-2014
Lot Release Volume of Blood Products in China by Product, 2008-2014
Market Size of Insulin Drugs in China, 2007-2014
Theoretical Capacity of Heparin Sodium API in China, 2008-2014
Market Size and YoY Growth of Heparin Preparations in China, 2007-2014
Market Size and Sales Volume of Recombinant Interferon in China, 2013-2019E
Market Size and Sales Volume of rhG-CSF in China, 2013-2019E
List of Primary Businesses of BD
Revenue and Operating Income of BD, FY2010-FY2014
Revenue Structure of BD by Business, FY2013-FY2014
Revenue Structure of BD by Region, FY2013-FY2014
BD’s Revenue Breakdown from Medical Business by Product, FY2011-FY2014 
Revenue Structure of Gerresheimer by Consumption Market, 2014
Revenue and Operating Income of Gerresheimer, 2009-2014
Revenue Breakdown of Gerresheimer by Business, 2009-2014
Revenue Structure of Gerresheimer by Region, 2014
Revenue and Profit of SCHOTT, FY2013-FY2014
Revenue Breakdown of SCHOTT by Region, FY2013-FY2014
SCHOTT’s Subsidiaries in China
Revenue and Net Income of Nipro, FY2010-FY2014
Revenue Structure of Nipro by Business, FY2013-FY2014
Revenue Structure of Nipro by Region, FY2014
Nipro’s Revenue from Glass Products Business and % of Total Revenue, FY2012-FY2014
Nipro’s Key Subsidiaries in China and Their Businesses
List of Main Products of Shandong Pharmaceutical Glass
Revenue and Net Income of Shandong Pharmaceutical Glass, 2008-2015
Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Product, 2008-2014
Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Region, 2008-2014
Gross Margin of Shandong Pharmaceutical Glass by Product, 2008-2014
Revenue and Gross Margin of Shandong Pharmaceutical Glass, 2014-2017E
Variety of Products and Main Products of Shandong Weigao Group Medical Polymer
Revenue and Net Income of Shandong Weigao Group Medical Polymer, 2009-2014
Revenue Breakdown of Shandong Weigao Group Medical Polymer, 2013-2014
Main High Value-added Conventional Medical Consumables of Shandong Weigao Group Medical Polymer
Revenue Breakdown of Shandong Weigao Group Medical Polymer by Region, 2008-2014
Prefilled Syringe Output and Sales of Shandong Weigao Group Medical Polymer, 2011-2014
Market Size of Pharmaceutical Packaging Industry in China, 2014-2017E

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

China Pharmaceutical Equipment Industry Report, 2011-2012

In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to Chin...

China Animal Vaccine Industry Report, 2010-2011

China animal vaccine industry has been fast-growing. The market maintained an average annual growth rate up to 13.6% in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0% YoY. With the in...

China Human Vaccine Industry Report, 2010-2011

With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统